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Within 2.5 years since SARS-COV-2 emergence, COVID-19 pandemic has caused more than 6.3 million registered
deaths and 530 million registered cases. The quick development of safe and effective vaccines was very important to
mitigate the sanitary crisis. However, the continuous emergence of virus variants with increasing transmissibility
continues to cause periodic outbreaks worldwide. The original vaccines keep protecting from severe disease and
death caused by variants, but not from transmission and mild disease. Thus, new and improved vaccines are
necessary, and updatable, multivalent pan-variant vaccines might be one way to control SARS-COV-2.
The spike (S) protein of SARS-COV-2, a highly glycosylated and very large protein (1380 amino acids), is a key target
for diagnostics, therapeutics (e.g. monoclonal antibodies) and vaccines. Very early in the pandemic, Wrapp et al.
(https://doi.org/10.1126/science.abb2507) produced the recombinant spike protein as a trimer stabilized in the prefusion
conformation and determined its structure by cryoelectron microscopy, providing evidence that it binds to the ACE-2
receptor. The stabilized spike trimer forms the basis of most approved COVID vaccines, across vaccine platforms.
In the present work, we studied the expression and purification of the trimeric prefusion-stabilized spike protein in
HEK293 cell lines and developed a platform process applicable to SARS-COV-2 variants (current - and potentially
future - ones). Parental HEK293 cells (NRC, Canada or Thermofisher, USA) were transfected by lipofection using
Lipofectamine 3000 (Thermofisher Scientific, USA) with a plasmid containing the gene encoding the spike protein. At
first, for the ancestral strain (Wuhan), we used a plasmid intended for transient expression kindly provided by
VRC/NIAID/NIH (USA). However, for the variants, we ordered synthetic genes (Genscript, USA) that were subcloned
in a plasmid intended for stable expression. After genetic modification, stably transfected cells were maintained in the
presence of G418 sulfate selection agent. After 3-4 weeks, stable cell pools were obtained and submitted to single
cell deposit (FACS Aria, BD Biosciences) in order to obtain clonally-derived cell lines. Documented research cell
banks of selected clones were cryopreserved. Batch and fed-batch cultivations were investigated in shake flasks and
bioreactors, using the chemically defined HEK TF culture medium and HEK FS feed solution (both Sartorius Xell,
Germany). For protein purification, different chromatographic techniques were investigated using Akta Purifier and
Akta Pilot systems. Detection of the spike protein secreted in cell culture supernatant was performed by immunoblot,
whereas UV280 (Nanodrop, Thermofisher, USA) was used for protein quantitation in purified samples.
After first expressing the spike protein in February 2020 by transient transfection, we developed a stable cell pool by
co-transfecting the same transient expression plasmid and an empty stable expression plasmid. This stable cell pool
allowed the generation of Wuhan protein that was used to develop serological tests and a hyperimmune equine
serum (Cunha et al., doi: 10.1016/j.isci.2021.103315; Alvim et al., in press) and was donated so far to over 90
laboratories in Brazil for basic or applied research.
Subsequently, we developed stable cell lines producing the spike protein of 8 different SARS-COV-2 variants (including
the variants of concern beta, gamma, delta, omicron BA.1 and omicron BA.2). For three variants, we also developed
clonally derived cell lines, and two more (omicron BA.1 and BA.2) are under way. We keep updating our variant spike
panel, and from design and order of a new variant gene to the first miligrams of protein produced by a stable cell pool,
we need approximately 60 days. Some agencies (such as Brazilian ANVISA) recommend the use of clonally derived
cell lines already for Phase I material, so 5 more months are needed to produce the protein from a clone.
We then developed a platform fed-batch process using chemically defined, animal component-free media, and this
fed-batch process was applied to the spike variants expressed so far. Regarding downstream processing, after
investigation of different chromatography strategies, we selected a purification process comprising an affinity
chromatography capture step that is based on a purification tag, a proteolytic tag cleavage step, and a polishing step
combining 3 chromatography techniques in tandem. The tag-based process allows the use of the same platform
purification process for all tested (and potentially future) spike variants, and enables adequate removal of critical
contaminants, such as residual DNA and host-cell protein (HCP). The resulting purified proteins were tested to
formulate monovalent and trivalent adjuvanted vaccines. The results obtained so far are highly promising, not only in
terms of process development (yield and cost of goods), but also in terms of the preclinical data that our group has
obtained so far in immunogenicity, challenge, and repeated-doses toxicology studies
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